Respiratory disease due to Bordetella pertussis has been recognized to be endemic in adolescent and adult ages, leading to the implementation of a booster vaccine for adolescents. [1] [2] [3] [4] The impact of B. pertussis on patients following allogeneic hematopoietic stem cell transplantation (HSCT) is unknown, and current guidelines do not include a universal recommendation for vaccination. 5, 6 Here, we report the mitigated clinical course of B. pertussis respiratory disease in an adolescent following allogeneic HSCT that may serve to underscore the presence of pertussis and the rationale for vaccination in this special population.
The patient was a 16-year-old, otherwise healthy male adolescent with acute B-lymphoblastic leukemia, who had received a matched related bone marrow transplantation in second complete remission following standard conditioning with total body irradiation plus etoposide. In the absence of graft-vs-host disease and other relevant medical problems, immunosuppressive therapy with cyclosporin A was tapered and discontinued around day þ 100. Comprehensive clinical and haematological follow-up examinations on days þ 100, þ 180 and þ 360 post-transplantation were unremarkable. At the last of these visits, all supportive care medication was discontinued and reimmunization initiated (including Hemophilus influenzae type b-(Hib), Hepatitis B-(HBV), diphtheria-(d), tetanus toxoid-(T), inactivated poliovirus-(IPV), 3-valent pneumococcal and influenzae vaccines).
Following a series of uneventful monthly follow-up examinations, the patient presented on day þ 605 for an unscheduled outpatient visit with a 2-weeks history of persistent, nonproductive cough without respiratory compromise, fever or other constitutional symptoms. There was no respiratory illness within the patient's family, but when asked about his peers at school, the patient stated that they all had a cough. Physical examination revealed an afebrile 16-year-old adolescent in no distress except for intermittent spells of a nonproductive cough. The respiratory rate was 15/min, and the oxygen saturation was 98%. There was no evidence for rhinorrhea, paranasal sinus infection or pharyngitis. Lung auscultation revealed normal breath sounds throughout. The remainder of the physical was unremarkable. A chest X-ray was within normal limits. Laboratory investigations showed a white blood cell count of 10.300/ul with 78% segmented and 2% eosinophilic granulocytes, 18% lymphocytes and 2% monocytes and a normal C-reactive protein. Two respiratory specimens were obtained from the pharynx and sent for viral diagnostics and Bordetella PCR assay. The patient was sent home with a follow-up appointment and the recommendation to complete the 14-day course of roxithromycin prescribed a few days earlier by his primary care physician.
On the next day, a PCR-enzyme-linked oligosorbent assay (PCR-ELOSA) was reported positive for B. pertussis (ampliWell Bordetella ID, Mikrogen, Martinsried, Germany). The respective PCR-ELOSA assay for Bordetella parapertussis (Mikrogen) and all viral diagnostics remained negative. At the follow-up clinic appointment on day þ 624, the patient continued to do well. His cough had improved to less frequent and partially productive, and there were no new respiratory signs or symptoms. A complete blood count with differential and the C-reactive protein were entirely normal; immune reconstitution was almost complete with CD19 þ and CD4 þ cell counts of 425 and 452/ul, respectively, and a serum IgG of 606 mg/dl. In order to confirm the diagnosis serologically by enzyme-linked immunosorbant assay (Virion/Serion, Wu¨rzburg, Germany), serum was obtained and again 42 and 147 days thereafter. The kinetics of B. pertussis-specific IgM and IgG antibodies revealed the characteristic concentration-time course of a primary B. pertussis infection (Figure 1) . The patient's further course was unremarkable. Two months after diagnosis, all respiratory symptoms had resolved, and a spirometric assessment obtained 8 months postdiagnosis was within normal limits.
B. pertussis respiratory infection is generally not perceived as relevant infectious problem following allogeneic HSCT. 6 Published data are currently limited to two cases that displayed similar clinical features as the one reported here. 7, 8 This lack of data may have several reasons. First, similar to the past situation in the general population, there may be a low awareness among transplant physicians of B. pertussis beyond infancy, resulting in a lack of recognition and diagnostic consideration as cause of respiratory illness. Second, trimethoprim/sulfamethoxazole, which is widely used in the post-HSCT setting for prophylaxis of Pneumocystis jiroveci pneumonitis, is active against B. pertussis 9 and may effectively prevent pertussis disease. Finally, apart from the potential effects of immunoglobulin substitution and adoptive transfer of cellular immunity from the donor, it is also conceivable that quantitative and qualitative defects of the lymphocyte compartment during the first months post-transplantation interfere with the pathogenesis of pertussis, whose morphological hallmark is peribronchial lymphoid hyperplasia with necrosis of epithelial cells and impaction of small airways by mucous and cellular debris. 10 According to this hypothesis, immaturity of the lymphocyte compartment would prevent severe disease in the immediate post-transplant setting, and infections during and following immune reconstitution would occur vastly in the setting of ambulatory primary care. Nevertheless, in the absence of systematic investigations, it is yet unknown whether and during which phase B. pertussis may occur in patients postallogeneic HSCT and whether it may cause more severe respiratory infection.
Universal vaccination against pertussis following allogeneic HSCT beyond the age of 7 years is currently not recommended, 5, 6 but it is performed in clinical practice by individual transplant centers. 11, 12 Although there is no reason to believe that adverse effects from acellular vaccines would be more severe in HSCT patients than in healthy individuals, 5 no data currently exist on their safety and immunogenicity in this setting. Given the evolving epidemiology and impact of pertussis disease in adolescents and adults and the favorable safety and immunogenicity data accrued in healthy individuals, a systematic investigation of the safety and immunogenicity of acellular pertussis vaccines in HSCT patients beyond the age of 7 years appears warranted.
In conclusion, this case report demonstrates that B. pertussis needs to be included in the differential diagnosis of persistent cough in patients following allogeneic HSCT. Although no specific data exist, there is no indication that antimicrobial therapy and supportive care are different from that in other populations. In analogy to the rationale of implementing a universal pertussis booster in normal adolescents, it appears time to investigate the safety and immunogenicity of 
